demonstrated statistically significant survival benefits with poractant alfa treatment when compared with the other two natural surfactants available for clinical use in the United States. These results suggest that neonatologists should carefully weigh their choice of surfactant therapy in their clinical practice."
The study presented today was supported by a research grant from Chiesi Farmaceutici of Parma, Italy, manufacturer of Curosurf Intratracheal Suspension, and Dey, L.P., US marketer of Curosurf.
"We are pleased to have supported this study and are impressed with its results," said J. Melville Engle, President and Chief Executive Officer of Dey, L.P. "To the extent that these data will affect clinical practice, these outcomes bode well for the health of premature infants and the peace of mind of their families."
Paolo Chiesi, Vice President, R&D Director of Chiesi Farmaceutici, concurred: "Curosurf is already the most widely used surfactant in the world, and we look forward to its being used to treat more babies suffering from RDS in the United States. We are delighted that this large data analysis so strongly validates the clinical value of Curosurf."
Contact: Harriet Ullman
Feinstein Kean Healthcare 7-May-2007Page: 1 2 3 Related biology news :1
. Pregnancy news -- Preterm delivery risk reduced by high-dose progesterone treatment2
. Preterm birth risk quickly and accurately detected with proteomic profiling3
. Prenatal stress keeps infants, toddlers up at night, study says4
. Nearly 28,000 US infants died in 20045
. Early exposure to indoor fungus molecules may protect infants against future allergies6
. Different approach needed to protect brains of premature infants7
. Mutant gene causes severe kidney disease in infants8
. A cognitive strategy shared by human infants and our great-ape kin9
. Full year of treatment helps infants and children with toxoplasmosis10
. Key nutrients critical for older infants development11
. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants